Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  2009-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.23.4823PMID 19597016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dermatologic symptoms associated with the multikinase inhibitor sorafenib.

  2009cited by this paper
• Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

  2009cited by this paper
• Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

  2008cited by this paper
• Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

  2008cited by this paper
• Diagnosis and Follow-Up of Keratoacanthoma-Like Lesions: Clinical-Histologic Study of 43 Cases

  2008cited by this paper
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.

  2008cited by this paper
• Keratoacanthomas associated with sorafenib therapy.

  2007cited by this paper
• Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine‐kinase inhibitor

  2006cited by this paper
• Immunolocalization and Expression of Vascular Endothelial Growth Factor Receptors (VEGFRs) and Neuropilins (NRPs) on Keratinocytes in Human Epidermis

  2006cited by this paper
• Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization.

  2006cited by this paper
• Cutaneous side-effects of kinase inhibitors and blocking antibodies.

  2005cited by this paper
• Keratoacanthoma: A Clinico‐Pathologic Enigma

  2004cited by this paper
• Cyclic AMP differentially regulates cell proliferation of normal human keratinocytes through ERK activation depending on the expression pattern of B-Raf

  2004cited by this paper
• Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.

  2004cited by this paper
• Multiple Keratoacanthomas Arising Post-UVB Therapy

  2004cited by this paper
• Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.

  2004cited by this paper
• Differentiating Squamous Cell Carcinoma from Keratoacanthoma Using Histopathological Criteria

  1999cited by this paper
• Keratoacanthoma.

  1994cited by this paper
• Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases.

  1993cited by this paper
• Multiple keratoacanthomas treated with oral retinoids.

  1990cited by this paper

• An effective multistage mouse model of esophageal carcinogenesis for preclinical and computational pathology applications

  2025cites this paper
• An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC.

  2024cites this paper
• Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm

  2024cites this paper
• Skin Malignancies Due to Anti-Cancer Therapies

  2024cites this paper
• Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers

  2024cites this paper
• Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

  2024cites this paper
• Progress in the study of ferroptosis in cancer treatment: State-of-the-Art.

  2023cites this paper
• Using human genetics to improve safety assessment of therapeutics

  2022cites this paper
• Multiple keratoacanthomas induced by treatment with dasatinib and bosutinib for chronic myeloid leukemia: A case report and literature review

  2022cites this paper
• Sorafenib-Related Basal Cell Carcinoma.

  2021cites this paper
• Dermatologic Adverse Effects of Anticancer Therapy III: Targeted and Immunotherapies

  2021cites this paper
• Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

  2021cites this paper
• Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report

  2021cites this paper
• Penile and scrotal infundibular cysts in an adolescent treated with sorafenib

  2021cites this paper
• Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity

  2021cites this paper
• Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors

  2021cites this paper
• A clinical and biological review of keratoacanthoma *

  2021cites this paper
• Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center

  2021cites this paper
• An unusual labial tumor: A case report and review

  2021cites this paper
• Recent progress in TGF-β inhibitors for cancer therapy.

  2020cites this paper
• Cutaneous adverse effects of biologic medications

  2020cites this paper
• Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review

  2020cites this paper
• Practical Guide to Dermatology: The Henry Ford Manual

  2020cites this paper
• Systemic medications linked to an increased risk for skin malignancy.

  2019cites this paper
• Common Cutaneous Side Effects of Anti-cancer Agents

  2019cites this paper
• Unraveling cancer lineage drivers in squamous cell carcinomas.

  2019cites this paper
• Keratoacantoma Like Squamous Cell Carcinoma and Basal Cell Carcinoma, Collision Tumor in the Skin

  2019cites this paper
• Deciphering the cells of origin of squamous cell carcinomas

  2018cites this paper
• Palmoplantar Keratoderma Like Drug Eruption Due to Sorafenib

  2018cites this paper
• Dermatologic Side Effects of Systemic Targeted Anticancer Therapy

  2018cites this paper
• Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use

  2017cites this paper
• Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers

  2017cites this paper
• Oesophageal Stem Cells and Cancer

  2017cites this paper
• Comprehensive pharmacological profiling of neurofibromatosis cell lines.

  2017cites this paper
• Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma

  2017cites this paper
• Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

  2017cites this paper
• Structural and Functional Characterization of RAF Allosteric Regulation

  2017cites this paper
• The Many Faces of the Paradoxical Response to BRAF Inhibitors

  2017cites this paper
• A case of keratoacanthoma in a patient receiving sorafenib for the treatment of hepatocellular carcinoma, which showed spontaneous disappearance after discontinuing sorafenib

  2017cites this paper
• Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.

  2017cites this paper
• Cytokeratin 17: An Adjunct Immunohistochemical Marker of Invasion in Squamous Neoplastic Skin Lesions

  2017cites this paper
• BRAF inhibitor‐associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management

  2017cites this paper
• Sorafenib with ASC‐J9® synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals

  2016cites this paper
• A single dividing cell population with imbalanced fate drives oesophageal tumour growth

  2016cites this paper
• Cutaneous manifestations of nontargeted and targeted chemotherapies.

  2016cites this paper
• Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer

  2016cites this paper
• Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

  2016cites this paper
• Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

  2016cites this paper
• Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.

  2016cites this paper
• Resolution of lung adenocarcinoma after discontinuation of ibrutinib

  2016cites this paper
• Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing

  2015cites this paper
• Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?

  2015cites this paper
• Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

  2015cites this paper
• Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.

  2015cites this paper
• Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

  2015cites this paper
• Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.

  2015cites this paper
• Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma

  2015cites this paper
• Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management

  2015cites this paper
• Multiple Keratoacanthomas, Philadelphia Chromosome+ Acute Lymphoblastic Leukemia, and Dasatinib: A Case Report

  2015influential citation
• Safety and efficacy of vemurafenib in BRAF V 600 E and BRAF V 600 K mutation-positive melanoma ( BRIM-3 ) : extended follow-up of a phase 3 , randomised , open-label study

  2015cites this paper
• mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  2014cites this paper
• Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

  2014influential citation
• Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

  2014cites this paper
• Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.

  2014cites this paper
• Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer

  2014cites this paper
• Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.

  2014influential citation
• NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis

  2014cites this paper
• Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.

  2014cites this paper
• Keratoacanthoma Clinical Behavior: A Systematic Review

  2014cites this paper
• The changes in the expression levels of follicular markers in keratoacanthoma depend on the stage: keratoacanthoma is a follicular neoplasm exhibiting infundibular/isthmic differentiation without expression of CK15

  2014cites this paper
• Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

  2014cites this paper
• Perforating folliculitis-like reaction related to sorafenib.

  2014cites this paper
• Brèves de l’AERIO

  2014cites this paper
• Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

  2014cites this paper
• Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics

  2014cites this paper
• Identification of novel molecular targets for cutaneous squamous cell carcinoma

  2014cites this paper
• Les toxicités cutanées des chimiothérapies aujourd’hui : étude rétrospective avec analyse dans un grand centre anti-cancéreux ; les effets secondaires cutanés des anti-BRAF et leur retentissement sur la qualité de vie : l’étude SKIN TARGET

  2014cites this paper
• Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab

  2014cites this paper
• Dermatologic Toxicities of Anticancer Therapy

  2014cites this paper
• Multiple squamous cell carcinomas following introduction of nilotinib

  2014cites this paper
• Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.

  2014cites this paper
• Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

  2013cites this paper
• Novedades en el diagnóstico de las toxicodermias

  2013cites this paper
• Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK

  2013cites this paper
• Phase I/II RAF kinase inhibitors in cancer therapy

  2013cites this paper
• Molecularly targeted therapies for melanoma

  2013cites this paper
• Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

  2013cites this paper
• Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs

  2013cites this paper
• Resistance to Targeted Therapies in Melanoma: New Insights

  2013cites this paper
• Dermatologic Side Effects of Systemic Anticancer Therapy

  2013cites this paper
• Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

  2013cites this paper
• Cutaneous toxicities of RAF inhibitors.

  2013cites this paper
• Kutane Nebenwirkungen der Kombinationstherapie mit Sorafenib und pegyliertem Interferon alfa‐2b bei metastasiertem Melanom (ADO SoraPeg‐Studie)

  2013cites this paper
• AnalysisofDermatologicEventsinVemurafenib-TreatedPatients WithMelanoma MARIOE.LACOUTURE, a MADELEINEDUVIC, b AXELHAUSCHILD, c VICTORG.PRIETO, d CAROLINEROBERT, e DIRKSCHADENDORF, f CAROLINEC.KIM, g CHRISTOPHERJ.MCCORMACK, h PATRICIAL.MYSKOWSKI, i OLIVIASPLEISS, j KERSTINTRUNZER, j FEISU, k BETTYNELS

  2013cites this paper
• Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

  2013cites this paper
• Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.

  2013cites this paper
• Understanding, recognizing, and managing toxicities of targeted anticancer therapies

  2013cites this paper
• Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)

  2013cites this paper
• Advances in the Diagnosis of Drug Eruptions

  2013cites this paper
• Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

  2013cites this paper